<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="308">
  <stage>Registered</stage>
  <submitdate>29/08/2005</submitdate>
  <approvaldate>12/09/2005</approvaldate>
  <actrnumber>ACTRN12605000362695</actrnumber>
  <trial_identification>
    <studytitle>Antioxidants in bipolar disorder: A double blind randomised placebo controlled trial of n-acetyl cysteine.</studytitle>
    <scientifictitle>Antioxidants in Bipolar Disorder: A double blind randomised placebo 
controlled trial investigating n-acetyl cysteine effects on a range of 
psychiatric rating scales</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Bipolar disorder</healthcondition>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Other mental health disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Other neurological disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>This is a six month treatment study with a four to six week post-discontinuation visit.  The trial involves 2g of n-acetyl cysteine per day in addition to the participants usual treatment.</interventions>
    <comparator>Placebo</comparator>
    <control>Placebo</control>
    <interventioncode>None</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Time to intervention for mood episode</outcome>
      <timepoint>When occurred</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>YMRS</outcome>
      <timepoint>At each trial visit. (Total of nine visits).</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>BDRS</outcome>
      <timepoint>At each trial visit. (Total of nine visits).</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Q-LES-Q</outcome>
      <timepoint>At each trial visit. (Total of nine visits).</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Slice/life</outcome>
      <timepoint>At each trial visit. (Total of nine visits).</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Life/rift</outcome>
      <timepoint>At each trial visit. (Total of nine visits).</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>SOFAS</outcome>
      <timepoint>At each trial visit. (Total of nine visits).</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>CGI </outcome>
      <timepoint>At each trial visit. (Total of nine visits).</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>GAF</outcome>
      <timepoint>At each trial visit. (Total of nine visits).</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>DSM-IV diagnosis of bipolar disorder (I, II or NOS), have had at least one mood episode within the last 12 months, have been on stable treatment for one month, have the capacity to consent and be on effective contraception.</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>Not stated</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria> Asthma, history of ulcers, respiritory insufficiency, any current systemic medical disorder, participants who are currently taking either 500mg of NAC/day, 200ug of selenium/day or 500 IU of Vitamin E/day and women pregnant or lactacting.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3 / Phase 4</phase>
    <anticipatedstartdate>1/01/2004</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>80</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Research Funds</primarysponsorname>
    <primarysponsoraddress>Victoria, Australia</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Other</fundingtype>
      <fundingname>Research Funds</fundingname>
      <fundingaddress>Victoria</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Other</sponsortype>
      <sponsorname>Mental Health Research Institute</sponsorname>
      <sponsoraddress>Parkville, Melbourne, Australia</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Barwon Health</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Bendigo Health Care Group</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>South West Area Mental Health Service (Werribee)</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Prof. Michael Berk</name>
      <address>The Geelong Hospital
Kitchener House
PO Box 281
Geelong VIC 3220</address>
      <phone>+61 3 52603154</phone>
      <fax />
      <email>mikebe@barwonhealth.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Ms. Olivia Dean</name>
      <address>The Geelong Hospital
Kitchener House
PO Box 281
Geelong VIC 3220</address>
      <phone>+61 3 93892973</phone>
      <fax />
      <email>odean@mhri.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>